For research use only. Not for therapeutic Use.
Nivolumab（Cat No.:A001234）is a monoclonal antibody used as an immunotherapy treatment for various cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin lymphoma. It works by blocking the PD-1 receptor on T-cells, enhancing the immune system’s ability to recognize and attack cancer cells. Nivolumab has shown significant efficacy in improving survival rates and delaying disease progression. Its role in checkpoint inhibition represents a breakthrough in cancer treatment, offering hope for patients with advanced or refractory cancers and contributing to the advancement of personalized oncology therapies.
| Catalog Number | A001234 |
| CAS Number | 946414-94-4 |
| Synonyms | Nivolumab;BMS 936558;MDX 1106;ONO 4538;Opdivo |
| Molecular Formula | NA |
| Purity | ≥95% |
| Target | PD-1 |
| Storage | Room Temperature |
| IUPAC Name | 3-methyl-5-methylsulfonyl-1-(2,2,4-trimethyl-3,4-dihydro-1H-quinolin-8-yl)pent-4-en-1-one;3-methyl-5-methylsulfonyl-1-(2,2,4-trimethyl-1H-quinolin-8-yl)pent-4-en-1-one;5-methylsulfonyl-1-(2,2,4-trimethyl-3,4-dihydro-1H-quinolin-8-yl)pent-4-en-1-one;5-methylsulfonyl-1-(2,2,4-trimethyl-1H-quinolin-8-yl)pent-4-en-1-one |
| InChI | InChI=1S/C19H27NO3S.C19H25NO3S.C18H25NO3S.C18H23NO3S/c2*1-13(9-10-24(5,22)23)11-17(21)16-8-6-7-15-14(2)12-19(3,4)20-18(15)16;2*1-13-12-18(2,3)19-17-14(13)8-7-9-15(17)16(20)10-5-6-11-23(4,21)22/h6-10,13-14,20H,11-12H2,1-5H3;6-10,12-13,20H,11H2,1-5H3;6-9,11,13,19H,5,10,12H2,1-4H3;6-9,11-12,19H,5,10H2,1-4H3 |
| InChIKey | VSTHRBNUEGPUOM-UHFFFAOYSA-N |
| SMILES | CC1CC(NC2=C1C=CC=C2C(=O)CCC=CS(=O)(=O)C)(C)C.CC1CC(NC2=C1C=CC=C2C(=O)CC(C)C=CS(=O)(=O)C)(C)C.CC1=CC(NC2=C1C=CC=C2C(=O)CCC=CS(=O)(=O)C)(C)C.CC1=CC(NC2=C1C=CC=C2C(=O)CC(C)C=CS(=O)(=O)C)(C)C |
